CAMP4 Therapeutics (CAMP): which funds own it

Who owns CAMP4 Therapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Janus Henderson Group, 12.2% (13G filed Jan 8, 2026), Coastlands Capital, 10.0% (13G/A filed Dec 11, 2025), Andrew J. Schwab, 9.9% (13D/A filed Aug 31, 2026), FMR, 9.5% (13G/A filed Feb 5, 2026) and Vivo Opportunity Fund Holdings, 7.4% (13G/A filed Feb 13, 2026). 5AM Ventures VII, L.P. is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were Jupiter Topco (12.1% of the shares), 5AM Venture Management (11.3%) and FMR (9.4%).

Sources:13G by Janus Henderson Group (Jan 8, 2026) ↗13G/A by Coastlands Capital (Dec 11, 2025) ↗13D/A by Andrew J. Schwab (Aug 31, 2026) ↗13G/A by FMR (Feb 5, 2026) ↗13G/A by Vivo Opportunity Fund Holdings (Feb 13, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 6, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• Jupiter Topco6.3 MType not verified · 10.05% of the companyno data
• 5AM Venture Management5.9 MPrivate equity or venture capital · 9.35% of the company0
• FMR4.9 MInvestment firm · 7.82% of the company−29 K
• Vivo Capitalconcentrated4.2 MInvestment firm · 6.77% of the company0
• Balyasny Asset Management2.6 MQuant or multi-manager · 4.10% of the company−57 K
• a16z Capital Management, L.L.C2.1 MPrivate equity or venture capital · 3.39% of the company0
• Adage Capital Partners Gp, L.l.c2.0 MInvestment firm · 3.12% of the company0
• Trails Edge Capital Partners1.9 MType not verified · 3.08% of the company−6,626
• BlackRock1.6 MIndex manager · 2.62% of the company+1.2 M
• Vanguard Capital Management1.5 MIndex manager · 2.44% of the company−1,279

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 80.3% of the shares · top 10: 63.7% · in index firms: 12.4% of the institutional total

Shares reported by the 61 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 6, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• Aug 4, 2026Routinefiling ↗

  Unregistered sale of equity securities (Item 3.02)

  «CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement»

• Jun 12, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Mar 24, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.